Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01469793 (Clinical Trial / DMOT4039A / RG7600)

Study Title
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer (NCT01469793)

Trial Description
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DMOT4039A (also known as RG7600)  in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Cohorts of patients will receive multiple ascending intravenous doses of DMOT4039A. Anticipated time on study treatment is up to 1 year or until disease progression occurs.

This trial is sponsored by Genentech. [1]

Study Data

  • Condition: Ovarian Cancer and Pancreatic Cancer
  • Interventions:
    • Drugs used in this trial
      • DMOT4039A (DMOT-4039A / RG7600 / RG 7600)
  • Phase: I
  • Enrollment: 71
  • Start: November 2011
  • Estimated Completion: July 2015
  • Last verified: July 2015

Study Schematic 

NCT01469793


Last Editorial review: July 29, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar